CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that new data on ponatinib, its investigational pan-BCR-ABL inhibitor, and ridaforolimus, an investigational mTOR inhibitor discovered by ARIAD and now being developed by Merck, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3 to 7, 2011.
